Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Expert Rev Hematol ; 13(1): 5-11, 2020 01.
Article in English | MEDLINE | ID: mdl-31657968

ABSTRACT

Introduction: Hemophilic arthropathy (HA) is a serious complication among hemophilic patients causing a wide range of morbidity due to the inflammatory reactions followed by repeated episodes of bleeding. This condition has recently been shown to be accompanied by angiogenesis. The cascade starts with iron accumulation leading to an increase in CD68+ and CD11b+ cells responsible for initiating the inflammation.Areas covered: During inflammation, different factors and cytokines such as interleukin 1 (IL-1), IL-6, and tumor necrosis factor α (TNF-α) actively play parts in the pathogenesis of HA and also angiogenesis. It has been demonstrated that different pro-angiogenic and angiogenic factors such as hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), oxidative stress and matrix metalloproteinases (MMPs) are also important in the pathogenesis of HA. Curcumin is known for its strong anti-inflammatory and anti-angiogenic potentials. This agent is able to inhibit the mentioned inflammatory and angiogenic factors such as IL-1, IL-6, TNF-α, VEGF, MMPs, and HIF-1α. Also, as well as anti-angiogenic and anti-inflammatory activity, curcumin has a strong antioxidant potential and can decrease oxidative stress.Expert opinion: It seems that curcumin could be considered as a possible agent for the treatment of HA through inhibition of inflammation, oxidative stress, and angiogenesis.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Curcumin/therapeutic use , Hemophilia A , Joint Diseases , Neovascularization, Pathologic , Collagenases/immunology , Cytokines/immunology , Hemophilia A/complications , Hemophilia A/drug therapy , Hemophilia A/immunology , Hemophilia A/pathology , Humans , Inflammation/drug therapy , Inflammation/etiology , Inflammation/immunology , Inflammation/pathology , Iron/immunology , Joint Diseases/drug therapy , Joint Diseases/etiology , Joint Diseases/immunology , Joint Diseases/pathology , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/etiology , Neovascularization, Pathologic/immunology , Neovascularization, Pathologic/pathology , Oxidative Stress/drug effects , Oxidative Stress/immunology
2.
Nutrients ; 9(1)2017 Jan 16.
Article in English | MEDLINE | ID: mdl-28275210

ABSTRACT

Chronic joint inflammatory disorders such as osteoarthritis and rheumatoid arthritis have in common an upsurge of inflammation, and oxidative stress, resulting in progressive histological alterations and disabling symptoms. Currently used conventional medication (ranging from pain-killers to biological agents) is potent, but frequently associated with serious, even life-threatening side effects. Used for millennia in traditional herbalism, medicinal plants are a promising alternative, with lower rate of adverse events and efficiency frequently comparable with that of conventional drugs. Nevertheless, their mechanism of action is in many cases elusive and/or uncertain. Even though many of them have been proven effective in studies done in vitro or on animal models, there is a scarcity of human clinical evidence. The purpose of this review is to summarize the available scientific information on the following joint-friendly medicinal plants, which have been tested in human studies: Arnica montana, Boswellia spp., Curcuma spp., Equisetum arvense, Harpagophytum procumbens, Salix spp., Sesamum indicum, Symphytum officinalis, Zingiber officinalis, Panax notoginseng, and Whitania somnifera.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/therapeutic use , Joint Diseases/drug therapy , Phytotherapy , Plant Preparations/therapeutic use , Plants, Medicinal/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Antioxidants/adverse effects , Antioxidants/chemistry , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , Ethnopharmacology , Humans , Joint Diseases/immunology , Joint Diseases/metabolism , Osteoarthritis/drug therapy , Osteoarthritis/immunology , Osteoarthritis/metabolism , Oxidative Stress/drug effects , Phytotherapy/adverse effects , Plant Extracts/adverse effects , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Plant Preparations/adverse effects , Plant Preparations/chemistry
3.
Joint Bone Spine ; 84(3): 263-266, 2017 May.
Article in English | MEDLINE | ID: mdl-27825568

ABSTRACT

Celiac disease is a chronic inflammatory autoimmune enteropathy based disorder that is triggered by the ingestion of gluten in genetically susceptible individuals. The global prevalence of 1% to 2% represents only the tip of the iceberg. The diagnosis is confirmed by positive specific antibody, anti-transglutaminase or anti-endomysium, specific lesions of the small intestine and a response to strict gluten-free diet. The diagnosis is difficult and often delayed because the clinical variability is very large, ranging from digestive clinical presentation "classic" to "atypical" symptoms, often extra-intestinal, that are sometimes attributed to a concomitant disease or a complication. Among them, there are frequent musculoskeletal manifestations such as osteoporosis and osteomalacia. In the absence of risk factor, osteoporosis, in a premenopausal women or in a man less than 55 years, more is if it is severe and refractory to medications, need to rheumatologists on the track of celiac disease in the absence of digestive symptoms. Osteomalacia is related to secondary hypovitaminosis D malabsorption. Supplementation by calcifediol, water-soluble vitamin D, may be indicated. Celiac disease is associated with an autoimmune disease in almost 1/3 of the cases. Knowing these potential associations allows earlier diagnosis in patients whose only manifestation, a concomitant disease. Anemia, chronic fatigue or unexplained polyarthralgia are symptoms associated with celiac disease to look for specific antibodies. The aim of early diagnosis is to prevent the emergence of other systemic disorders and avoid complications such as bone fractures and cancer, especially intestinal lymphoma. Non-celiac gluten intolerance is a new entity defined by symptomatology similar to that of celiac disease induced by the ingestion of gluten and disappearing after crowding-out, among patients without specific antibodies and without intestinal lesion of celiac disease. This entity is a cause, at least in part, of increasing interest in gluten-free diet in the general population.


Subject(s)
Bone Diseases/immunology , Celiac Disease/diagnosis , Glutens/adverse effects , Hypersensitivity , Joint Diseases/immunology , Celiac Disease/immunology , Humans
4.
J Virol ; 89(15): 8063-76, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26018160

ABSTRACT

UNLABELLED: Arthritogenic alphaviruses such as Ross River virus (RRV) and chikungunya virus (CHIKV) cause large-scale epidemics of severe musculoskeletal disease and have been progressively expanding their global distribution. Since its introduction in July 2014, CHIKV now circulates in the United States. The hallmark of alphavirus disease is crippling pain and inflammation of the joints, a similar immunopathology to rheumatoid arthritis. The use of glycans as novel therapeutics is an area of research that has increased in recent years. Here, we describe the promising therapeutic potential of the glycosaminoglycan (GAG)-like molecule pentosan polysulfate (PPS) to alleviate virus-induced arthritis. Mouse models of RRV and CHIKV disease were used to characterize the extent of cartilage damage in infection and investigate the potential of PPS to treat disease. This was assessed using histological analysis, real-time PCR, and fluorescence-activated cell sorting (FACS). Alphaviral infection resulted in cartilage destruction, the severity of which was alleviated by PPS therapy during RRV and CHIKV clinical disease. The reduction in cartilage damage corresponded with a significant reduction in immune infiltrates. Using multiplex bead arrays, PPS treatment was found to have significantly increased the anti-inflammatory cytokine interleukin-10 and reduced proinflammatory cytokines, typically correlated with disease severity. Furthermore, we reveal that the severe RRV-induced joint pathology, including thinning of articular cartilage and loss of proteoglycans in the cartilage matrix, was diminished with treatment. PPS is a promising new therapy for alphavirus-induced arthritis, acting to preserve the cartilage matrix, which is damaged during alphavirus infection. Overall, the data demonstrate the potential of glycotherapeutics as a new class of treatment for infectious arthritis. IMPORTANCE: The hallmark of alphavirus disease is crippling pain and joint arthritis, which often has an extended duration. In the past year, CHIKV has expanded into the Americas, with approximately 1 million cases reported to date, whereas RRV continues to circulate in the South Pacific. Currently, there is no licensed specific treatment for alphavirus disease, and the increasing spread of infection highlights an urgent need for therapeutic intervention strategies. Pentosan polysulfate (PPS) is a glycan derivative that is orally bioavailable, has few toxic side effects, and is currently licensed under the name Elmiron for the treatment of cystitis in the United States. Our findings show that RRV infection damages the articular cartilage, including a loss of proteoglycans within the joint. Furthermore, treatment with PPS reduced the severity of both RRV- and CHIKV-induced musculoskeletal disease, including a reduction in inflammation and joint swelling, suggesting that PPS is a promising candidate for drug repurposing for the treatment of alphavirus-induced arthritis.


Subject(s)
Cartilage/immunology , Chikungunya Fever/drug therapy , Chikungunya virus/physiology , Glycosaminoglycans/administration & dosage , Joint Diseases/drug therapy , Pentosan Sulfuric Polyester/administration & dosage , Animals , Cartilage/drug effects , Cartilage/virology , Chikungunya Fever/immunology , Chikungunya Fever/virology , Disease Models, Animal , Humans , Joint Diseases/immunology , Joint Diseases/virology , Mice , Mice, Inbred C57BL
5.
Phytomedicine ; 19(10): 882-9, 2012 Jul 15.
Article in English | MEDLINE | ID: mdl-22673798

ABSTRACT

Rheumatoid arthritis is characterized by the imbalance of T cells, which leads to increased pro-inflammatory and reduced anti-inflammatory cytokines. Modulating the balance among T cells is crucial for the treatment of RA. Kirenol is a major diterpenoid components of Herba Siegesbeckiae, which has been applied for arthritic therapy for centuries. Since prior research showed Kirenol exhibited anti-inflammatory effect in rats, in this study we have evaluated the effect and mechanism of bioactive Kirenol in a rat model of collagen-induced arthritis (CIA) on modulation of T cells. After immunization with bovine type II collagen (CII), Wistar rats were orally administered saline (CIA group), 2 mg/kg Kirenol or 2 mg/kg prednisolone daily for 30 days. The severity of arthritis was clinically and histologically assessed. The numbers of CD4⁺CD25⁺Foxp3⁺ T regulatory cells (Tregs) and IFNγ⁺CD4⁺ and IL4⁺CD4⁺ T cells were determined by flow cytometry, the mRNA expression level of Foxp3 was quantified by RT-PCR, cytokine levels were measured by ELISA and CII-induced cell proliferation was quantified in vitro. Kirenol significantly delayed the occurrence and reduced the disease severity of CIA. Histological analysis confirmed Kirenol suppressed joint inflammation and inhibited cartilage and bone destruction, compared to the CIA group. Kirenol also upregulated the mRNA expression of Foxp3, increased the numbers of CD4⁺CD25⁺Foxp3⁺ and IL4⁺CD4⁺ T cells, and reduced the number of IFNγ⁺CD4⁺ T cells. Kirenol reduced the levels of TNF-α, IL-17A and IL-6 in synovial fluid and TNF-α, IL-17A and IFN-γ in serum, and increased the serum levels of IL-4, IL-10 and TGF-ß1. In addition, Kirenol inhibited the ability of CII to induce splenocyte, PBMC and lymph node cell proliferation in vitro, compared to cells from CIA rats. In conclusion, these results suggest that Kirenol may be a potential immunosuppressant for the treatment for rheumatoid arthritis.


Subject(s)
Arthritis, Experimental/drug therapy , Arthritis, Rheumatoid/immunology , Asteraceae/chemistry , Cytokines/blood , Diterpenes/therapeutic use , Immunosuppressive Agents/therapeutic use , Phytotherapy , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/drug therapy , Bone and Bones/drug effects , Bone and Bones/pathology , CD4-Positive T-Lymphocytes/metabolism , Cartilage/drug effects , Cartilage/pathology , Cattle , Cell Proliferation/drug effects , Collagen Type II , Diterpenes/pharmacology , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Female , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Immunosuppressive Agents/pharmacology , Inflammation/drug therapy , Inflammation/immunology , Inflammation/metabolism , Inflammation Mediators/metabolism , Interleukin-2 Receptor alpha Subunit/metabolism , Joint Diseases/drug therapy , Joint Diseases/immunology , Joint Diseases/metabolism , Leukocytes, Mononuclear/metabolism , Lymph Nodes/cytology , Lymph Nodes/drug effects , Prednisolone/pharmacology , Prednisolone/therapeutic use , RNA, Messenger/metabolism , Rats , Rats, Wistar , Severity of Illness Index , Spleen/cytology , Spleen/drug effects , Synovial Fluid/drug effects , Synovial Fluid/metabolism , T-Lymphocytes, Regulatory/metabolism
7.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 23(6): 527-30, 2007 Jun.
Article in Chinese | MEDLINE | ID: mdl-17553349

ABSTRACT

AIM: To investigate the effect of the overall alkali of Traditional Chinese Medicine tongbiling(TBL) which comprises brucine and strychnine alkaloids on collagen induced-arthritis(CIA) and study its paharmacological mechanisms of cellular immunity. METHODS: Bovine CII was emulsified in Freund's incomplete adjuvant. Wistar rats were injected with Type II collagen intradermally at the base of the tail. After swelling, CIA groups were, randomly divided into physiological saline group and treatment group. Then the swelling of the rats' hindlimbs was evaluated. The whole body of the rats treated on 35 th days was photographed by mammography X-Ray. 96 joints in erosion scoring system and 100 joints in joint spacing narrow(JSN) scoring system were used to observe the joint destruction of CIA from X-Ray comprehensively and objectively. After the rats were killed, the third proximal claw pad of the right hindlimb and left forelimb were stained by HE dying, Neutrophil, lymphocyte, plasmacyte infiltration and hyperplasia of synoviocytes were assessed. Then MTT and Western blot were used to determine the effect of the overall alkali of TBL on proliferation of Jurkat cells and ERK1/2 phosphorylation of Jurkat cells, respectively. RESULTS: Inflammation of CIA joints was aggravated quickly. The swelling of CIA rats treated by MTX and overall alkali of TBL for 35 days was relieved (P<0.05). MTX and overall alkali of TBL inhibited the hyperplasia of synoviocytes. Overall alkali of TBL inhibited the infiltration of lymphocyteS and plasmacytes. Overall alkali of TBL inhibited the proliferation and ERK1/2 phosphorylation of Jurkat cells. CONCLUSION: Overall alkali of TBL could relieve joint inflammation and destruction of CIA rats by blocking the MAPK cell signalling pathway to inhibit the activation and proliferation of T cells. Our study might provide an experimental basis for treatment of rheumatoid arthritis with overall alkali of TBL.


Subject(s)
Alkaloids , Arthritis, Experimental/drug therapy , Arthritis, Experimental/immunology , Drugs, Chinese Herbal , Immunity, Cellular/drug effects , Joint Diseases/drug therapy , Joint Diseases/immunology , Alkaloids/pharmacology , Alkaloids/therapeutic use , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Cell Proliferation/drug effects , Cells, Cultured , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Female , Joint Diseases/chemically induced , Joint Diseases/metabolism , Joint Diseases/pathology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation/drug effects , Random Allocation , Rats , Rats, Wistar , Signal Transduction/drug effects
8.
Musculoskeletal Care ; 1(1): 44-57, 2003 Mar.
Article in English | MEDLINE | ID: mdl-20217663

ABSTRACT

This article provides an overview of the immune system with a specific focus on the role of biologic therapies in treating the consequences of an altered immune response as seen in rheumatoid arthritis (RA). Cytokines are powerful chemical messengers that have a significant role to play in activating an inflammatory response. Two dominant cytokines have been identified as crucial in the inflammatory process that can be seen in RA-tumour necrosis factor alpha (TNFalpha) and interleukin-1. The term 'biologic' is used to describe biologically engineered therapies that are specifically designed to prevent pro-inflammatory cytokines inducing an inflammatory response. Research trials and now clinical practice have clearly demonstrated a significant benefit to patients receiving biologic therapies. The responsibility of the practitioner is to ensure a sound knowledge of biologic therapies, to understand the essential aspects of care and to recognize the importance of guidance documents available to support management and, ultimately, the long-term provision of safe and effective administration of these therapies.


Subject(s)
Antirheumatic Agents/immunology , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/therapy , Biological Therapy , Clinical Trials as Topic , Humans , Immune System/immunology , Immunologic Factors/immunology , Immunologic Factors/therapeutic use , Joint Diseases/immunology , Joint Diseases/therapy , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/therapeutic use
9.
Lik Sprava ; (1): 97-100, 1999.
Article in Russian | MEDLINE | ID: mdl-10424014

ABSTRACT

Kept under medical surveillance in a health resort setting were 52 patients with disorders of the parodontium and large joints. All patients were given a complex therapy involving dietotherapy, therapeutic exercise, hydrotherapy, mud-treatment. Those patients having parodontium diseases were also prescribed topical treatment (chloride-sodium mouth baths and mud applications to the gingiva area). The main group subjects were also exposed to VMF using the unit for low-frequency therapy "Gradient-1". Laboratory means were also made use of, as a complex of biochemical tests characterizing changes in lipid metabolism. The level of the natural bodily resistance was determined by nitroblue tetrazolium test (NBT-test). The condition of the parodontium was evaluated by the Loë-Silness index. Adaptive reactions were studied by the lymphocytes-to-segmented neutrophils ratio. Adoption of therapy involving physiobalneofactors in patients with afflictions of the parodontium tissues and large joints makes for development of favourable in prognostic respect adaptive reactions.


Subject(s)
Joint Diseases/therapy , Magnetics/therapeutic use , Periodontal Diseases/therapy , Adaptation, Physiological , Adult , Biomarkers/blood , Combined Modality Therapy , Female , Health Resorts , Humans , Joint Diseases/blood , Joint Diseases/immunology , Joint Diseases/physiopathology , Magnetics/instrumentation , Male , Middle Aged , Periodontal Diseases/blood , Periodontal Diseases/immunology , Periodontal Diseases/physiopathology , Ukraine
SELECTION OF CITATIONS
SEARCH DETAIL